Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ZOLEDRONIC vs ACTONEL WITH CALCIUM (COPACKAGED)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.
ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men,Treatment of glucocorticoid-induced osteoporosis,Paget's disease of bone,Hypercalcemia of malignancy,Prevention of skeletal-related events in multiple myeloma and bone metastases from solid tumors
Treatment and prevention of postmenopausal osteoporosis,Treatment of glucocorticoid-induced osteoporosis,Treatment of Paget's disease of bone
5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.
Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.
The terminal elimination half-life of zoledronic acid is approximately 146 hours (range 44-196 hours) after a single intravenous dose. This long half-life reflects slow release from bone rather than systemic clearance. Despite the prolonged terminal phase, the clinical effect (suppression of bone resorption) persists for weeks to months. The initial distribution half-life is about 0.23 hours, and the intermediate half-life is about 1.75 hours.
Terminal elimination half-life of risedronate is approximately 20 hours for the 5 mg daily dose and 480 hours for the 35 mg weekly dose due to prolonged retention in bone; clinically, the drug accumulates in bone and is slowly released.
Zoledronic acid is not metabolized in humans and is eliminated unchanged primarily by the kidneys via glomerular filtration and tubular secretion.
Risedronate is not metabolized and is eliminated unchanged primarily via renal excretion.
Zoledronic acid is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 39 ± 16% of the administered dose is recovered in urine within 24 hours, with the remainder (up to 60%) retained in bone and slowly released over time. Fecal excretion is negligible (<1%). Renal clearance is dose-dependent and correlates with creatinine clearance. Dose adjustment is required for creatinine clearance <35 m L/min.
Risedronate is eliminated primarily via renal excretion, with approximately 50% of an absorbed dose excreted unchanged in urine. Unabsorbed drug is eliminated in feces. Total clearance is about 100 m L/min.
Zoledronic acid is approximately 22-40% bound to plasma proteins, primarily to albumin. Binding is concentration-independent over the therapeutic range, but the exact binding proteins are not fully characterized. The unbound fraction (60-78%) is pharmacologically active.
Risedronate is approximately 24% bound to plasma proteins.
The volume of distribution (Vd) is 4.3-7.6 L/kg (approximately 300-530 L in a 70 kg adult). This large Vd indicates extensive distribution into bone, where it binds to hydroxyapatite, and also to soft tissues. The Vd increases with body weight. The rapid initial distribution phase reflects high affinity for bone (exposed hydroxyapatite surfaces).
Volume of distribution for risedronate is approximately 6.3 L/kg, indicating extensive distribution into bone and other tissues.
Zoledronic acid has negligible oral bioavailability (<0.5%) due to high polarity and poor intestinal absorption. Only intravenous administration is used clinically (IV infusion over at least 15 minutes for the 4 mg dose or 30-60 minutes for higher doses). Subcutaneous, intramuscular, and other routes are not recommended due to risk of local reactions and incomplete absorption.
Oral bioavailability of risedronate is low, averaging 0.63% for the 5 mg tablet when taken under fasting conditions; administration with food reduces bioavailability significantly (by up to 50%).
For osteoporosis: not recommended if Cr Cl <35 m L/min. For Paget's disease or hypercalcemia: not recommended if Cr Cl <35 m L/min. For malignancy-related bone disease: if Cr Cl 30-60 m L/min, reduce dose to 3.5 mg; if Cr Cl <30 m L/min, not recommended. All doses should be administered only after correcting hypovolemia and monitoring serum creatinine.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-49 m L/min: no dose adjustment needed. For Cr Cl ≥50 m L/min: no adjustment.
No dose adjustment required for mild to moderate hepatic impairment; not studied in severe hepatic impairment, use with caution.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
Not recommended for use in pediatric patients; safety and efficacy not established.
Not indicated for use in pediatric patients. Safety and efficacy not established.
No specific dose adjustment required based on age alone; renal function should be assessed and dose adjusted accordingly as elderly patients are more likely to have decreased renal function.
No specific dose adjustment required. Caution in patients with decreased renal function; monitor renal status. Increased risk of hypocalcemia if calcium intake inadequate.
Zoledronic acid is not recommended for use in patients with severe renal impairment (Cr Cl <35 m L/min) due to increased risk of renal toxicity. Acute renal failure and renal impairment may occur after single or multiple doses, especially in patients with pre-existing renal disease or dehydration.
None
Renal toxicity and acute renal failure, particularly in patients with impaired renal function or dehydration,Electrolyte disturbances (e.g., hypocalcemia, hypophosphatemia, hypomagnesemia),Osteonecrosis of the jaw (ONJ), especially in cancer patients with dental risk factors,Atypical femur fractures with long-term use,Severe musculoskeletal pain,Bronchospasm in aspirin-sensitive asthmatic patients
Hypocalcemia must be corrected before therapy,Severe renal impairment (Cr Cl <30 m L/min) is not recommended,Esophageal irritation: instruct patients to swallow with full glass of water and not to lie down for 30 minutes,Osteonecrosis of the jaw (rare, mainly with cancer doses),Atypical femur fractures (rare, with long-term use),Avoid concomitant use with other bisphosphonates
Hypocalcemia,Severe renal impairment (Cr Cl <35 m L/min),Pregnancy (category D),Breastfeeding,Hypersensitivity to zoledronic acid or any component of the formulation
Hypocalcemia,Severe renal impairment (Cr Cl <30 m L/min),Inability to sit or stand upright for at least 30 minutes,Hypersensitivity to risedronate or any component,Use in patients with esophageal abnormalities that delay emptying (e.g., stricture, achalasia)
Avoid high-calcium foods (e.g., dairy, fortified cereals) within 2 hours of taking oral calcium supplements; however, no direct food interactions with IV zoledronic acid. Maintain adequate calcium and vitamin D intake as part of therapy.
Risedronate absorption is significantly reduced by food, especially dairy products, calcium-rich foods, and beverages other than plain water. Avoid all food, beverages (except plain water), and other medications for at least 30 minutes after the dose. Calcium supplement should be taken with a meal to enhance absorption.
Zoledronic acid (a bisphosphonate) is FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and limited human data. In animal studies, it caused skeletal and visceral anomalies, reduced fetal weight, and increased fetal mortality. Use is contraindicated in pregnancy due to risk of fetal skeletal abnormalities and hypocalcemia. First trimester exposure carries the highest risk for skeletal teratogenicity. Second and third trimester exposure may cause fetal hypocalcemia and bone demineralization.
Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during pregnancy. No adequate studies in pregnant women; use only if clearly needed. Calcium carbonate: Generally considered safe but excessive doses may cause hypercalcemia-related fetal risks. First trimester: Limited data, avoid if possible. Second/third trimester: Use only if maternal benefit outweighs fetal risk.
It is unknown if zoledronic acid is excreted in human breast milk. Due to potential for bone growth suppression and hypocalcemia in the infant, breastfeeding is not recommended during therapy and for at least 1 month after the last dose. M/P ratio is not available.
Risedronate: Unknown if excreted in human milk; not recommended due to potential for bone growth inhibition. Calcium: Excreted in breast milk at normal maternal intake levels; no adverse effects reported. M/P ratio: Unknown for risedronate; calcium M/P ratio approximately 1.1.
No specific dosing adjustments are recommended because zoledronic acid is contraindicated in pregnancy. If used inadvertently, no dosage adjustment is advised; therapy should be discontinued. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance), but data insufficient to guide dose changes.
Risedronate: No specific dose adjustments are recommended in pregnancy due to lack of data; generally avoided. Calcium: No dose adjustment needed; maintain recommended daily intake (1000-1300 mg/day). Pregnancy may increase calcium absorption but no dose change required for supplementation.
Monitor serum creatinine before each dose; avoid in Cr Cl <35 m L/min. Assess for hypocalcemia and correct vitamin D deficiency before initiation. Administer as a 15-minute IV infusion; do not bolus. Use with caution in patients with asthma (aspirin-sensitive) due to risk of bronchospasm. For osteoporosis, ensure adequate calcium and vitamin D intake. Acute phase reaction (fever, myalgia) common after first dose; premedicate with acetaminophen if needed.
Actonel (risedronate) with calcium (copackaged) is used for osteoporosis. Administer risedronate on an empty stomach with plain water, at least 30 minutes before first food, drink, or other medications. Wait at least 30 minutes after risedronate before taking the calcium supplement. Calcium can interfere with risedronate absorption.
You may experience flu-like symptoms (fever, muscle pain) after your first infusion; this usually resolves in 1-3 days.,Take calcium and vitamin D supplements as directed to prevent low calcium levels.,Drink plenty of water before and after infusion to protect your kidneys.,Report any jaw pain, numbness, or swelling; this could be a sign of osteonecrosis of the jaw.,Avoid dental procedures (extractions, implants) for at least 3 months after your dose.,This medication is given by intravenous infusion every 3-4 weeks for cancer or once yearly for osteoporosis.
Take the risedronate tablet first thing in the morning, at least 30 minutes before eating or drinking anything except plain water.,Swallow the risedronate tablet whole with a full glass of plain water (6-8 oz). Do not crush, chew, or suck the tablet.,Do not lie down for at least 30 minutes after taking risedronate to reduce risk of esophageal irritation.,After taking risedronate, wait at least 30 minutes before taking the calcium supplement provided in the copack.,Take the calcium supplement with food or after a meal to improve absorption and reduce stomach upset.,Report any symptoms of esophageal problems (difficulty or pain on swallowing, heartburn, or retrosternal pain) or jaw pain (possible osteonecrosis of the jaw).
"Concomitant use of olopatadine, an antihistamine with weak anticholinergic properties, and zoledronic acid, a bisphosphonate, may lead to an increased risk of renal toxicity. Olopatadine can cause urinary retention, while zoledronic acid is primarily eliminated unchanged by the kidneys; additive nephrotoxic effects may occur, particularly in patients with pre-existing renal impairment or dehydration. This interaction may result in elevated serum creatinine, acute kidney injury, or renal failure."
"Tranilast, an antiallergic agent, may increase the risk of nephrotoxicity when coadministered with zoledronic acid, a bisphosphonate primarily eliminated by renal excretion. This interaction could lead to elevated serum creatinine and acute kidney injury, particularly in patients with pre-existing renal impairment or dehydration. Clinical outcomes may include delayed renal recovery or prolonged hospitalization."
"The coadministration of Nabumetone, a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits cyclooxygenase (COX) enzymes, and Zoledronic acid, a bisphosphonate that inhibits osteoclast-mediated bone resorption, may lead to an increased risk of renal adverse effects, particularly acute kidney injury (AKI). Nabumetone can reduce renal prostaglandin synthesis, leading to decreased renal blood flow and glomerular filtration rate, which may impair the elimination of Zoledronic acid and exacerbate its nephrotoxic potential. This interaction is especially concerning in patients with pre-existing renal impairment, dehydration, or those taking other nephrotoxic medications."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ZOLEDRONIC vs ACTONEL WITH CALCIUM (COPACKAGED), answered by our medical review team.
ZOLEDRONIC is a Bisphosphonate that works by Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.. ACTONEL WITH CALCIUM (COPACKAGED) is a Bisphosphonate and Calcium Supplement that works by ACTONEL WITH CALCIUM (COPACKAGED) contains risedronate sodium, a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone and inhibiting farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway. This leads to reduced bone turnover and increased bone mineral density. The calcium component is for supplementation to prevent hypocalcemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ZOLEDRONIC and ACTONEL WITH CALCIUM (COPACKAGED) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ZOLEDRONIC is: 5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.. The standard adult dose of ACTONEL WITH CALCIUM (COPACKAGED) is: Actonel (risedronate) 35 mg orally once weekly, taken with 6-8 oz of plain water at least 30 minutes before breakfast. Calcium supplement (e.g., 1250 mg calcium carbonate) taken with food at a different time of day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ZOLEDRONIC and ACTONEL WITH CALCIUM (COPACKAGED) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ZOLEDRONIC is classified as Category C. Zoledronic acid (a bisphosphonate) is FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and limited human data. In animal studies, it caused skeleta. ACTONEL WITH CALCIUM (COPACKAGED) is classified as Category C. Risedronate: Pregnancy Category C. Bisphosphonates accumulate in bone and are released slowly; theoretical risk of fetal skeletal abnormalities if exposure occurs before or during . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.